MBG453, VENETOCLAX, VENETOCLAX, AZACITIDINE, VENETOCLAX
CMBG453B12206B
Phase 2 small_molecule active
Quick answer
MBG453, VENETOCLAX, VENETOCLAX, AZACITIDINE, VENETOCLAX for intermediate, high or very high risk MDS in adult patients chronic Myelomonocytic Leukemia - 2 (CMML-2) Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- intermediate, high or very high risk MDS in adult patients chronic Myelomonocytic Leukemia - 2 (CMML-2) Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active